地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18327026838
传真:17754422825
邮箱:sales@amyjet.com

艾美捷科技代理Cisbio 品牌。
Cisbio是一家专注于药物发现和生物分析的公司,提供创新的高通量筛选技术和生物分析工具,支持药物研发、毒理学研究和生物标志物发现。Cisbio公司采用 HTRF® 技术,实现高效、精确的药物发现和生物分析; 提供灵活的定制高通量筛选和生物分析服务,其产品用于药物筛选、靶点验证和药效评估;用于毒性测试和安全评估;用于生物标志物筛选和验证;用于细胞生物学、分子生物学和生物化学研究。。
Cisbio公司主要产品与服务:
(1)HTRF® 技术:提供基于 HTRF®(均相时间分辨荧光)技术的高通量筛选平台,用于药物发现和生物分析。
(2)生物分析工具:提供多种生物分析工具,如细胞活性检测、蛋白质相互作用分析和生物标志物检测。
(3)定制服务:根据客户需求,提供定制化的高通量筛选和生物分析服务。
(4)技术咨询与支持:提供药物发现和生物分析相关的咨询和技术支持服务。

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://arbor.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

日本和光纯药工业株式会社“Wako”系列试剂涵盖了全面的生物化学、分析化学、有机化学、环境分析、食品·医药品分析、高纯度及认证标准品等多类,约50万种试剂。Wako尤以致力于某些当前特殊的高端领域,如:癌症病的研究及有效防治、农兽药残留物分析、中药研究、食品科学和水质分析等关乎人类健康的生命科学研究,并且独树一帜,经历大量成功实验应用案例从而奠定了其在试剂领域中强而有力的地位。
Wako的主要产品包括:
生物化学类
分析化学类
环境分析用试剂
合成用试剂
素材研究用试剂
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://arbor.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Wako"> Wako
艾美捷科技代理Epitope Diagnostics全系列抗体及试剂盒产品。
Epitope Diagnostics是一家经过ISO 13845认证的医疗器械制造公司,位于圣地亚哥的索伦托谷生物技术中心。Epitope专门从事全球医疗设备和诊断行业的分析开发和制造。公司涉足领域包括胃肠道,心血管,感染和自身免疫性疾病,以及肿瘤/癌症和钙/骨代谢。Epitope Diagnostics Inc. (EDI) strives to develop, manufacture, and market the highest quality and most innovated in-vitro diagnostics (IVD) products to the global research, pharmaceutical, and healthcare community. We seek to become a major contributor in resolving the unmet medical needs of the world.
Epitope Diagnostics公司的主要产品包括:
| ANTIBODIES | ||
| MAB30699 | Anti-MMAE Monoclonal Antibody | |
| MAB30699b | Biotinylated Anti-MMAE Monoclonal Antibody | |
| MAB30700 | Anti-MMAF Monoclonal Antibody | |
| MAB30700b | Biotinylated Anti-MMAF Monoclonal Antibody | |
| 30698 | Anti-DM1 Polyclonal Antibody | |
| 30699 | Anti-MMAE Polyclonal Antibody | |
| 30700 | Anti-MMAE Polyclonal Antibody | |
| 30618 | Anti-Human FGF-21 N-terminal Specific Antibody, Affinity Purified | |
| 30661 | Anti-Human FGF-21 C-terminal Specific Antibody, Affinitiy Purified | |
| 30704 | Anti-Human Chromogranin A Monoclonal Antibody, Murine | |
| 30705 | Anti-Human Chromogranin A Polyclonal Antibody, Sheep | |
| 30706 | Anti-Human Chromogranin A N-terminal Polyclonal Antibody, Rabbit | |
| 30713 | Anti-Human Chromogranin A N/mid-regional Polyclonal Antibody, Rabbit | |
| 30714 | Anti-Human Chromogranin A C/mid-regional Polyclonal Antibody, Rabbit | |
| 30715 | Anti-Human Chromogranin A C-terminal Polyclonal Antibody, Rabbit | |
| 30657 | Anti-Human NGAL Polyclonal Antibody (IgG), Sheep | |
| 30658 | Anti-Human NGAL Polyclonal Antibody, Sheep, Affinity Purified | |
| TUMOR MARKERS & CANCER RESEARCH | ||
| KT-810 | Human Pepsinogen I ELISA Kit | 96 tests/kit |
| KT-811 | Human Pepsinogen II ELISA Kit | 96 tests/kit |
| KT-812 | Human Chromogranin A ELISA Kit (1st generation) | 96 tests/kit |
| KT-820 | Human Chromogranin A ELISA Kit (2nd generation) | 96 tests/kit |
| KT-855 | Human Chromogranin A ELISA Kit (2nd generation, wide range) | 96 tests/kit |
| KT-817 | Human Neuron Specific Enolase ELISA Kit | 96 tests/kit |
| KT-850 | q-FOB™ Quantitative Fecal Occult Blood Test ELISA Kit | 96 tests/kit |
| 30210 | Fecal Sample Collection Device for q-FOB™ | 50 tubes/kit |
| KT-111 | FOB Cassette Test Kit | 20 tests/kit |
| KT-705 | Intact Brentuximab Vedotin ELISA KIt | 96 tests/kit |
| KT-706 | Trastuzumab Emtansine EIA Kit | 96 tests/kit |
| KTR-755 | Humanized Anti-Her2/neu (Herceptin/trastuzumab) ELISA Kit | 96 tests/kit |
| KTR-756 | DM1 ADC EIA Kit | 96 tests/kit |
| KTR-757 | MMAE ADC EIA Kit | 96 tests/kit |
| KTR-758 | MMAF ADC EIA Kit | 96 tests/kit |
| KTR-782 | Intact MMAE ADC ELISA Kit | 96 tests/kit |
| KTR-783 | Intact MMAF ADC ELISA Kit | 96 tests/kit |
| GASTROINTESTINAL DISEASE-Serum ELISA Kits | ||
| KT-810 | Human Pepsinogen I ELISA Kit | 96 tests/kit |
| KT-811 | Human Pepsinogen II ELISA Kit | 96 tests/kit |
| KT-830 | Human Anti-Gliadin IgA EIA Kit | 96 tests/kit |
| KT-831 | Human Anti-Gliadin IgG EIA Kit | 96 tests/kit |
| KT-845 | Human Anti-Giardia lamblia IgA ELISA Kit | 96 tests/kit |
| KT-846 | Human Anti-Giardia lamblia IgG ELISA Kit | 96 tests/kit |
| KT-847 | Human Anti-Giardia lamblia IgM ELISA Kit | 96 tests/kit |
| GASTROINTESTINAL DISEASE-Fecal ELISA Kits | ||
| KT-824 | Qualitative Fecal H. pylori Antigen ELISA Kit | 96 tests/kit |
| KT-826 | Quantitative Fecal H. pylori Antigen ELISA Kit | 96 tests/kit |
| KT-828 | Fecal C. difficile GDH ELISA Kit | 96 tests/kit |
| KT-834 | Fecal C. difficile Toxin A ELISA Kit | 96 tests/kit |
| KT-835 | Fecal C. difficile Toxin B ELISA Kit | 96 tests/kit |
| KT-836 | Fecal C. difficile Toxin A & B ELISA Kit | 96 tests/kit |
| KT-837 | Fecal E. coli 0157 ELISA Kit | 96 tests/kit |
| KT-838 | Fecal Giardia lamblia Antigen ELISA Kit | 96 tests/kit |
| KT-839 | Fecal Cryptosporidium parvum Antigen ELISA Kit | 96 tests/kit |
| KT-841 | Fecal Rotavirus Antigen ELISA Kit | 96 tests/kit |
| KT-842 | Fecal Adenovirus Antigen ELISA Kit | 96 tests/kit |
| KT-849 | Quantitative Fecal Calprotectin ELISA Kit | 96 tests/kit |
| KT-850 | q-FOB™ Quantitative Fecal Occult Blood Test ELISA Kit | 96 tests/kit |
| KT-853 | Quantitative Fecal NGAL ELISA Kit | 96 tests/kit |
| KT-880 | Quantitative Fecal/Urine Myeloperoxidase ELISA Kit | 96 tests/kit |
| GASTROINTESTINAL DISEASE-Fecal Sample Collection Kits | ||
| KT-854 | Fecal H. pylori Sample Collection Kit | 50 tubes/kit |
| KT-864 | Fecal H. pylori/GDH/Toxin A&B Sample Collection Kit | 48 tubes/kit |
| KT-843 | Fecal Calprotectin Sample Collection Kit | 50 tubes/kit |
| 30210 | q-FOB™ Fecal Sample Collection Device | 50 tubes/kit |
| KT-844 | Fecal MPO Sample Collection Kit | 48 tubes/kit |
| KT-884 | Fecal NGAL Sample Collection Kit | 48 tubes/kit |
| FPC200 | Fecal Ova/Parasite Concentration Kit | 50 tubes/kit |
| GASTROINTESTINAL DISEASE-Rapid Tests | ||
| KT-313 | EpiTuub® Immunochemical Fecal Occult Blood Rapid Test Kit | 30 tests/kit |
| KT-917 | EpiTuub® Fecal Rotavirus Antigen Rapid Test Kit | 30 tests/kit |
| KT-918 | EpiTuub® Fecal Adenovirus Antigen Rapid Test Kit | 30 tests/kit |
| KT-920 | EpiTuub® Fecal Calprotectin Rapid Test Kit | 30 tests/kit |
| KT-921 | EpiTuub® Fecal Calprotectin Rapid Test Kit | 10 tests/kit |
| KT-922 | EpiTuub® Calprotectin/i-FOB DUO Test | 30 tests/kit |
| KT-926 | EpiTuub® Fecal Rota-Adeno Duo Antigen Rapid Test Kit | 30 tests/kit |
| KT-927 | EpiTuub® Fecal Giardia lamblia Antigen Rapid Test Kit | 30 tests/kit |
| KT-928 | EpiTuub® Fecal Cryptosporidiun parvum Antigen Rapid Test Kit | 30 tests/kit |
| KT-929 | EpiTuub® Fecal H. pylori Antigen Rapid Test Kit | 30 tests/kit |
| KT-935 | EpiTuub® Fecal C. difficile Antigen Rapid Test Kit | 30 tests/kit |
| GASTROINTESTINAL DISEASE-Strip Test Kit | ||
| KT-313s | Immunochemical Fecal Occult Blood Strip Test Kit | 50 strips/kit |
| KT-917s | Fecal Rotavirus Antigen Strip Test Kit | 50 strips/kit |
| KT-918s | Fecal Adenovirus Antigen Strip Test Kit | 50 strips/kit |
| KT-920s | Fecal Calprotectin Strip Test Kit | 50 strips/kit |
| KT-927s | Fecal Giardia lamblia Antigen Strip Test Kit | 50 strips/kit |
| KT-928s | Fecal Cryptosporidium parvum Antigen Strip Test Kit | 50 strips/kit |
| KT-929s | Fecal H. pylori Antigen Strip Test Kit | 50 strips/kit |
| KT-935s | Fecal C. difficile Antigen Strip Test Kit | 50 strips/kit |
| GASTROINTESTINAL DISEASE-Cassette Test Kits | ||
| KT-111 | FOB Cassette Test Kit | 20 tests/kit |
| KT-112 | Calprotectin Cassette Test Kit | 20 tests/kit |
| KT-113 | H. pylori Cassette Test Kit | 20 tests/kit |
| INFECTIOUS DISEASE | ||
| KT-851 | Varicella Zoster Virus (VZV) IgG ELISA Kit | 96 tests/kit |
| KT-867 | HAV IgG ELISA Kit | 96 tests/kit |
| KT-868 | HAV IgM ELISA Kit,μ-Capture Method | 96 tests/kit |
| KT-869 | Total HAV Antibody ELISA Kit | 96 tests/kit |
| KT-897 | Zika Virus IgG ELISA Kit | 96 tests/kit |
| KT-898 | Zika Virus IgM ELISA Kit,μ-Capture Method | 96 tests/kit |
| KT-1011 | HBeAg ELISA Kit | 96 tests/kit |
| KT-1015 | H. pylori IgG ELISA Kit | 96 tests/kit |
| KT-1018 | HEV IgG ELISA Kit | 96 tests/kit |
| KT-1019 | HEV IgM ELISA Kit,μ-Capture Method | 96 tests/kit |
| KTR-1020 | Toxoplasma gondii IgG ELISA Kit | 96 tests/kit |
| KTR-1021 | Toxoplasma gondii IgM ELISA Kit,μ-Capture Method | 96 tests/kit |
| KTR-1022 | Rubella IgG ELISA Kit | 96 tests/kit |
| KTR-1023 | Rubella IgM ELISA Kit,μ-Capture Method | 96 tests/kit |
| KTR-1024 | Cytomegalovirus (CMV) IgG ELISA Kit | 96 tests/kit |
| KTR-1025 | Cytomegalovirus (CMV) IgM ELISA Kit,μ-Capture Method | 96 tests/kit |
| KT-1026 | HSV 1+2 IgG ELISA Kit,μ-Capture Method | 96 tests/kit |
| KT-1027 | HSV 1+2 IgM ELISA Kit,μ-Capture Method | 96 tests/kit |
| KT-1028 | HSV-1 IgG ELISA Kit | 96 tests/kit |
| KT-1029 | HSV-1 IgM ELISA Kit,μ-Capture Method | 96 tests/kit |
| KT-1030 | HSV-2-IgG ELISA Kit | 96 tests/kit |
| KT-1031 | HSV-2 IgM ELISA Kit,μ-Capture Method | 96 tests/kit |
| KT-1032 | Coronavirus COVID-19 IgG ELISA Kit - qualitative, N protein target, CE marked | 96 tests/kit |
| KT-1033 | Coronavirus COVID-19 IgM ELISA Kit - qualitative, N protein target, CE marked | 96 tests/kit |
| KT-1034 | COVID-19 Nucleocapsid IgG Quantitative ELISA Kit - CE marked | 96 tests/kit |
| KTR-1035 | Quantitative SARS-CoV-2 Spike Protein IgG ELISA - CE marked | 96 tests/kit |
| KTR-1036 | Quantitative SARS-CoV-2 Neutralizing Antibody ELISA - CE marked | 96 tests/kit |
| CARDIOVASCULAR DISEASE | ||
| KT-800 | Human Fetuin-A ELISA Kit | 96 tests/kit |
| KT-900 | High Sensitive Human Fetuin-A ELISA Kit | 96 tests/kit |
| KT-883 | Human Plasma NGAL ELISA Kit | 96 tests/kit |
| KT-885 | Plasma Calprotectin ELISA Kit | 96 tests/kit |
| KT-890 | Quantitative Serum/Plasma Myeloperoxidase ELISA Kit | 96 tests/kit |
| CALCIUM/BONE METABOLISM | ||
| KT-809 | Human Osteocalcin (1-43/49) ELISA Kit | 96 tests/kit |
| KT-715 | Total 25-OH Vitamin D EIA Kit (Two wash steps) | 96 tests/kit |
| KT-815 | Total 25-OH Vitamin D EIA Kit (Three wash steps) | 96 tests/kit |
| KT-888 | Human Intact PTH ELISA Kit | 96 tests/kit |
| KT-896 | Human VDBP ELISA Kit | 96 tests/kit |
| KT-819 | Human Growth Hormone ELISA Kit | 96 tests/kit |
| KT-840 | Human Anti-CaSR IgG ELISA Kit | 96 tests/kit |
| ENDOCRINOLOGY/DIABETES | ||
| KT-804 | Human Anti-Müllerian Hormone ELISA Kit | 96 tests/kit |
| KT-809 | Human Osteocalcin (1-43/49) ELISA Kit | 96 tests/kit |
| KT-819 | Human Growth Hormone ELISA Kit | 96 tests/kit |
| KT-871 | Active GLP-1 (7-36) ELISA Kit | 96 tests/kit |
| KT-876 | Total GLP-1 ELISA Kit | 96 tests/kit |
| KT-602 | Total GLP-1 ELISA Kit | 96 tests/kit |
| KT-910 | GLP-1 Sample Solid Phase Extraction Kit | 50 columns/kit |
| KTR-873 | Human FGF-21 N-terminal specific ELISA Kit | 96 tests/kit |
| KTR-874 | Human FGF-21 C-terminal specific ELISA Kit | 96 tests/kit |
| KT-879 | Human Intact FGF-21 ELISA Kit | 96 tests/kit |
| KT-886 | Human Insulin ELISA Kit | 96 tests/kit |
| KT-887 | Human High Sensitive Insulin ELISA Kit | 96 tests/kit |
| KTR-888 | Human Intact PTH ELISA Kit | 96 tests/kit |
| KT-881 | Human C-peptide ELISA Kit | 96 tests/kit |
| KT-882 | Human ACTH ELISA Kit | 96 tests/kit |
| KT-891 | Human High Sensitive C-peptide ELISA Kit | 96 tests/kit |
| AUTOIMMUNE DISEASE | ||
| KT-802 | Human Anti-FcεRIα Autoantibody ELISA Kit | 96 tests/kit |
| KT-803 | Human Anti-IgE Autoantibody ELISA Kit | 96 tests/kit |
| KT-830 | Human Anti-Gliadin IgA EIA Kit | 96 tests/kit |
| KT-831 | Human Anti-Gliadin IgG EIA Kit | 96 tests/kit |
| KT-832 | Human Anti-Tg IgG ELISA Kit | 96 tests/kit |
| KT-833 | Human Anti-TPO IgG ELISA Kit | 96 tests/kit |
| KT-840 | Human Anti-CaSR IgG ELISA Kit | 96 tests/kit |
| MISCELLANEOUS KITS | ||
| KT-805 | HAMA (Human Anti-Mouse Antibody) ELISA Kit | 96 tests/kit |
| KT-806 | HAHA (Human Anti-Human Antibody) ELISA Kit | 96 tests/kit |
| KT-807 | MAHA (Mouse Anti-Human Antibody) ELISA Kit | 96 tests/kit |
| KT-751 | Haptoglobin Immunoturbidimetric Assay | Inquire |
<
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://arbor.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Epitope Diagnostics全系列抗体及试剂盒产品"> 艾美捷科技代理Epitope Diagnostics全系列抗体及试剂盒产品
QED Bioscience致力于为生物医药行业提供各类高品质抗体。
QED Bioscience has been designing and manufacturing antibodies for over 20 years, and throughout our history, our goals have remained unchanged: provide the best antibody products and services on the market and support our clients with the expertise and assistance they should expect from a full-spectrum antibody company like QED.
QED Bioscience develops novel monoclonal and polyclonal antibody products for our academic, biotechnology, diagnostic and pharmaceutical research clients. We develop these antibodies using the client’s small molecule, protein, or peptide targets, or by utilizing the target cDNA. We are a full-service corporation, and offer additional immunochemistry services such as purification and conjugation so that we can provide our clients with an antibody product that will work specifically within their system. We also develop monoclonal antibodies with pharmacological activity for enzyme neutralization and inhibition of receptor-ligand interactions, and anti-idiotypic antibodies.
QED Bioscience的主要产品包括:
Agriculture and Food Science Antibodies
Anti-Immunoglobulin Antibodies
Apoptosis Antibodies
Autophagy Antibodies
BioWarfare Antibodies
Cancer Research Antibodies
Cell Adhesion Molecule Antibodies
Coagulation Factor Antibodies
DNA/RNA/Oxidative Stress Antibodies
Drug Antibodies
Enzymes and Enzyme Inhibitor Antibodies
Epitope Tag Antibodies
Growth Factors/Cytokines/Receptor Antibodies
Heat Shock and Stress Protein Antibodies
Hormones and Serum Protein Antibodies
Infectious Disease Antibodies
Ion Channel Antibodies
Matrix Protein/MMP Antibodies
Neuroscience and Signal Transduction Antibodies
Phospho-specific Antibodies
Protein Transcription Antibodies
Reproductive Biology Antibodies
Secondary Antibodies
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

艾美捷科技提供Biomol品牌产品。
Biomol是一家德国综合性的生命科学产品供应商,目前有来自40个品牌的52万余种产品。
With a growing portfolio of 520,000 products from more than 40 suppliers, Biomol has been connecting researchers with products to support their discoveries for over 50 years. We combine our understanding of life science research with a curated collection of products from specialized manufacturers to meet the needs of researchers.
Biomol的主要产品包括:
Antibodies
Assays
Biological Samples
Chemicals
Cytokines
Kits
Plasmids
Primers
Proteins & Peptides
Accessory Reagents
" data-original="http://arbor.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Biomol"> Biomol
TiterMax®佐剂被用于增强免疫反应。TiterMax®佐剂有着跟弗氏佐剂相同的功效,但具有更安全、更易用的特点,是弗氏佐剂的理想代替产品。
TiterMax® adjuvants are used to produce cell mediated and humoral responses in research animals. TiterMax® adjuvants were developed to meet the specific needs of investigators for immunoadjuvants that are at least as effective as Freund's Complete Adjuvant, safer and easier to use. They are an attractive alternative to Freund's Complete Adjuvant for use by researchers in inducing antibody to diverse antigens. The key to the potency of TiterMax® adjuvants lies both in the immunostimulatory activity of their components and in the fact that they form a stable water-in-oil emulsion. TiterMax® adjuvants contain three essential ingredients: Proprietary block copolymers, squalene, a metabolizable oil, and a unique microparticulate stabilizer. Like Freund's Complete Adjuvant, TiterMax® adjuvants can be used with a wide variety of antigens because they can entrap any antigen in a water-in-oil emulsion. TiterMax® adjuvants aid in the antigens effective presentation to the immune system without the toxic effects of Freund's Complete Adjuvant.
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://arbor.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="TiterMax"> TiterMax
艾美捷科技代理SeraCare对照及参比物质。
艾美捷科技有限公司,自2018年与SeraCare(现隶属于LGC Clinical Diagnostics)合作以来,长期为中国客户提供包括SeraSeq系列参比物质,领域包括肿瘤、生殖健康和遗传病。SeraCare研发和生产一系列临床参比物质,可以用于任何研发阶段,以确保临床基因组学检测结果的准确性。
SeraCare参比物质涵盖的范围:
1)Next Generation Sequencing
2)Sanger Sequencing
3)Real-time PCR and digital PCR (dPCR)
4)Microarray
主要特点
1)Ready-to-use reference materials covering clinically-relevant variants and all variant types - SNVs, INDELS, CNVs, and RNA fusions
2)Highly multiplexed - provide significantly more data per NGS run, saving sequencing costs
3)Available in multiple formats to suite different workflow needs - purified DNA & RNA, ctDNA, encapsulated ctDNA in plasma, and FFPE
4)Manufactured in cGMP-compliant, ISO 13485-certified facilities
5)Stringent product release testing - all variants qualified by dPCR for allele frequencies or copy numbers
| 参比物质 | 货号 | 规格 |
| Seraseq® Whole Transcriptome RNA Seq Mix | 0710-2129 | 1 x 20 µl |
| Seraseq® Unmethylated ctDNA Mutation Mix | 0710-3088 | 1 x 25 µl |
| Seraseq® Tumor Mutation DNA Mix v2 AF 7 HC | 0710-0095 | 1 x 25 µl |
| Seraseq® Tumor Mutation DNA Mix v2 AF 10 HC | 0710-0094 | 1 x 25 µl |
| Seraseq® Tri-Level Tumor Mutation DNA Mix v2 HC | 0710-0097 | 1 x 25 µl |
| Seraseq® TNA (DNA/RNA) WT Mix | 0710-1580 | 2 x 20 µl |
| Seraseq® Solid Tumor CNV Mix, +6 copies | 0710-2867 | 1 x 20 µl |
| Seraseq® Solid Tumor CNV Mix, +3 copies | 0710-2866 | 1 x 20 µl |
| Seraseq® Solid Tumor CNV Mix, +12 copies | 0710-2868 | 1 x 20 µl |
| Seraseq® NTRK Fusion RNA Mix | 0710-1696 | 1 x 20 µl |
| Seraseq® Myeloid Mutation DNA Mix | 0710-0408 | 1 x 25 µl |
| Seraseq® Myeloid Fusion RNA Mix | 0710-0407 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix WT | 0710-2646 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix AF1% | 0710-2649 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix AF0.5% | 0710-2648 | 1 x 25 µl |
| Seraseq Myeloid ctDNA Mix AF0.1% | 0710-2647 | 1 x 25 µl |
| Seraseq® MSI Reference Panel Mix AF5% | 0710-1675 | 2 x 15 µl |
| Seraseq® MSI Reference Panel Mix AF20% | 0710-1676 | 2 x 15 µl |
| Seraseq® Methylated ctDNA Mutation Mix | 0710-3089 | 1 x 25 µl |
| Seraseq® Lymphoma DNA Mutation Mix | 0710-2203 | 1 x 25 µl |
| Seraseq™ Lung & Brain CNV Mix, + 6 copies | 0710-0415 | 1 x 20 µl |
| Seraseq® Lung & Brain CNV Mix, + 3 copies | 0710-0414 | 1 x 20 µl |
| Seraseq® Lung & Brain CNV Mix, + 12 copies | 0710-0416 | 1 x 20 µl |
| Seraseq® HRD gDNA Negative Mix | 0710-2881 | 2 x 20 µl |
| Seraseq® HRD gDNA Low-Positive Mix | 0710-2880 | 2 x 20 µl |
| Seraseq® HRD gDNA High-Positive Mix | 0710-2879 | 2 x 20 µl |
| Seraseq® gDNA TMB Reference Panel Mix | 0710-2463 | 5 x 20 µl |
| Seraseq® gDNA TMB Mix Score 9 | 0710-1325 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 7 | 0710-1326 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 26 | 0710-1323 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 20 | 0710-1324 | 2 x 500 ng |
| Seraseq® gDNA TMB Mix Score 13 | 0710-1586 | 2 x 10 µl |
| Seraseq® gDNA MSI-High Mix | 0710-1670 | 1 x 20 µl |
| Seraseq® gDNA BRCA1/2 LGR Somatic Mutation Mix | 0730-0567 | 1 x 25 µl |
| Seraseq® gDNA BRCA1/2 LGR Inherited Mutation Mix | 0730-0568 | 1 x 25 µl |
| Seraseq® Fusion RNA Mix v4 | 0710-0497 | 1 x 25 µl |
| Seraseq® FFPE WT (DNA/RNA) Reference Material | 0710-0137 | 1 x 10 µm |
| Seraseq® FFPE TMB RM Score 9 | 0710-1308 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 7 | 0710-1310 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 26 | 0710-1307 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 20 | 0710-1309 | 2 x 10 µm |
| Seraseq® FFPE TMB RM Score 13 | 0710-1618 | 2 x 10 um |
| Seraseq® FFPE Solid Tumor CNV Reference Materials | 0710-2865 | 1 x 10 µm |
| Seraseq® FFPE NTRK Fusion RNA Reference Material | 0710-1031 | 1 x 10 µm |
| Seraseq® FFPE MSI-High RM | 0710-2236 | 1 x 10 um |
| Seraseq® FFPE Lymphoma DNA Reference Material | 0710-2202 | 1 x 10 µm |
| Seraseq® FFPE HRD Negative RM | 0710-2644 | 1 x 10 µm |
| Seraseq® FFPE HRD Low-Positive RM | 0710-2645 | 1 x 10 µm |
| Seraseq® FFPE HRD High-Positive RM | 0710-2643 | 1 x 10 µm |
| Seraseq® FFPE Tumor Fusion RNA v4 Reference Material | 0710-0496 | 1 x 10 µm |
| Seraseq® FFPE BRCA1/2 LGR Reference Material | 0730-0564 | 1 x 10 µm |
| Seraseq® ctDNA Reference Material v2 WT | 0710-0208 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF2% | 0710-0203 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF1% | 0710-0204 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF0.5% | 0710-0205 | 1 x 5 mL |
| Seraseq® ctDNA Reference Material v2 AF0.125% | 0710-0207 | 1 x 5 mL |
| Seraseq® ctDNA Mutation Mix v2 WT | 0710-0144 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF2% | 0710-0139 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF1% | 0710-0140 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF0.5% | 0710-0141 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF0.25% | 0710-0142 | 1 x 25 µl |
| Seraseq® ctDNA Mutation Mix v2 AF0.125% | 0710-0143 | 1 x 25 µl |
| Seraseq® ctDNA MRD Panel Mix | 0710-2146 | 4 x 20 µl |
| Seraseq® ctDNA Complete™ Reference Material WT (0%) | 0710-0674 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF5% | 0710-0669 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF2.5% | 0710-0670 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF1% | 0710-0671 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF0.5% | 0710-0672 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Reference Material AF0.1% | 0710-0673 | 1 x 5 mL |
| Seraseq® ctDNA Complete™ Mutation Mix WT (0%) | 0710-0533 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF5% | 0710-0528 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF2.5% | 0710-0529 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF1% | 0710-0530 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF0.5% | 0710-0531 | 1 x 25 µl |
| Seraseq® ctDNA Complete™ Mutation Mix AF0.1% | 0710-0532 | 1 x 25 µl |
| Seraseq® Compromised FFPE WT (DNA/RNA) RM | 0710-1710 | 1 x 10 µm |
| Seraseq® Compromised FFPE Tumor DNA RM | 0710-1492 | 1 x 10 µm |
| Seraseq® Breast CNV Mix, + 6 copies | 0710-0412 | 1 x 20 µl |
| Seraseq® Breast CNV Mix, + 3 copies | 0710-0411 | 1 x 20 µl |
| Seraseq® Breast CNV Mix, + 12 copies | 0710-0413 | 1 x 20 µl |
| Seraseq® Blood TMB Mix Score 7 | 0710-2087 | 3 x 20 µl |
| Seraseq® Blood TMB Mix Score 26 | 0710-2090 | 3 x 20 µl |
| Seraseq® Blood TMB Mix Score 20 | 0710-2089 | 3 x 20 µl |
| Seraseq® Blood TMB Mix Score 13 | 0710-2088 | 3 x 20 µl |
| Seraseq® Turner Syndrome (XO) Reference Material | 0720-0952 | 1 x 1 mL |
| Seraseq® Trisomy 21 Male-Matched Reference Material | 0720-0167 | 1 x 1 mL |
| Seraseq® Trisomy 21 Female-Matched Reference Material | 0720-0168 | 1 x 1 mL |
| Seraseq® Trisomy 18 Male-Matched Reference Material | 0720-0171 | 1 x 1 mL |
| Seraseq® Trisomy 18 Female-Matched Reference Material | 0720-0172 | 1 x 1 mL |
| Seraseq® Trisomy 13 Male-Matched Reference Material | 0720-0779 | 1 x 1 mL |
| Seraseq® Trisomy 13 Female-Matched Reference Material | 0720-0780 | 1 x 1 mL |
| Seraseq® Triple X Syndrome (XXX) Reference Material | 0720-1069 | 1 x 1 mL |
| Seraseq® PGT-A Trisomy 21 Reference Material | 0720-0775 | 1 x 10 µl |
| Seraseq® PGT-A Trisomy 18 Reference Material | 0720-0776 | 1 x 10 µl |
| Seraseq® PGT-A Trisomy 13 Reference Material | 0720-0777 | 1 x 10 µl |
| Seraseq® PGT-A Euploid Reference Material | 0720-0778 | 1 x 10 µl |
| Seraseq® Klinefelter Syndrome (XXY) Reference Material | 0720-0953 | 1 x 1 mL |
| Seraseq® Jacobs Syndrome (XYY) Reference Material | 0720-0954 | 1 x 1 mL |
| Seraseq® Euploid Male-Matched Reference Material | 0720-0169 | 1 x 1 mL |
| Seraseq® Euploid Female-Matched Reference Material | 0720-0170 | 1 x 1 mL |
| Seraseq® 22q11 Male-Matched Reference Material | 0720-0173 | 1 x 1 mL |
| Seraseq® 22q11 Female-Matched Reference Material | 0720-0174 | 1 x 1 mL |
| Seraseq® Inherited Cancer DNA Mix v1 | 0730-0003 | 1 x 200 µL |
| Seraseq® gDNA BRCA1/2 LGR Inherited Mutation Mix | 0730-0568 | 1 x 25 µL |
| Seraseq® FFPE BRCA1/2 LGR Reference Material | 0730-0564 | 1 x 10 µm |
| Seraseq® Cardiomyopathy Reference Material | 0740-0021 | 1 x 200 µL |

艾美捷科技代理Tatua大拓品牌。
▌公司介绍
大拓位于新西兰畜牧中心地带,是新西兰历史最悠久的乳制品公司,创立于1914年。大拓研发生产专业蛋白胨,用于诊断培养基、发酵培养基、益生菌、生物制药和细胞培养行业,其蛋白胨都符合清真和犹太洁食标准。

更多详情请咨询→

全国免费热线:400-6800-868
直拨专线:+86-027-59626688;18771997407
客服QQ一:17754422825;
客服QQ二:18771149750
▌产品系列
大拓能够提供多样化的蛋白胨组合,以适应全球发酵和益生菌培养基细分市场的一系列应用需求。我司代理的产品类别包括乳糖蛋白胨及植物蛋白胨。
| 乳糖蛋白胨 |
大拓 (Tatua) 提供一系列源自新西兰、无BSE/TSE风险的纯净奶源的乳蛋白胨产品。
● 酪蛋白胨(清真胰蛋白胨):其化学组成、成分和物理特性均经过精心设计,以匹配更传统的胰蛋白酶消化酪蛋白(胰蛋白胨)产品的规格。
● 乳清蛋白胨(乳白蛋白酶解物):能够支持苛养菌的生长,常用于需要特定氨基酸谱的益生菌应用领域。
大拓 (Tatua) 的乳蛋白胨产品组合涵盖广泛的优势,包括:
● 过滤级产品:提供澄清度与热稳定性
● 非过滤级产品:更具成本效益
● 清真 (Halal) 与洁食 (Kosher) 认证
● 多种游离氨基酸谱 (FAA profiles):以支持最佳生长性能
| Product | Protein Source | Filtered | pH | Total Nitrogen | Amino Nitrogen | AN/TN | Ash | Features / Benefits |
| EHCK | Casein | No | 6.6 | 13.80% | 5.50% | 39.90% | 3.50% | ● Cost effective nitrogen source |
| HCP275 | Casein | Yes | 6.9 | 13.60% | 4.30% | 31.80% | 5.50% | ● Halal alternative to tryptone ● Meets pancreatic digest of casein USP criteria |
| HCP321 | Casein | Yes | 6.8 | 13.60% | 5.80% | 42.50% | 4.50% | ● Halal alternative to tryptone ● Good source of free amino acids |
| HCP512 | Casein | Yes | 6.8 | 14.30% | 2.60% | 18.20% | 4.00% | ● Specially designed for use in biopharma fermentations |
| Tatua 2400 | Casein | Yes | 6.9 | 13.40% | 4.40% | 32.90% | 5.80% | ● Supports growth of fastidious bacteria ● Halal alternative to tryptone |
| Tatua 2016 | Whey | Yes | 6.4 | 12.20% | 4.90% | 40.40% | 4.50% | ● Supports growth of fastidious bacteria |
| 植物蛋白胨 |
大拓 (Tatua)将酶解技术和下游加工技术应用于非乳制品蛋白原料,提供无动物成分和/或无过敏原特性的蛋白胨解决方案,作为传统(动物源)蛋白胨的替代品。
● Tatua大豆蛋白胨:是某些诊断培养基配方(如 TSA 和 TSB)的重要组成部分,并且在益生菌发酵应用中表现成熟可靠。
● Tatua豌豆蛋白胨:旨在解决大豆蛋白胨可能引起的大豆过敏原问题而开发,适用于益生菌应用。
<| Product | Protein Source | Filtered | pH | Total Nitrogen | Amino Nitrogen | AN/TN | Ash | Features / Benefits |
| HSP320 | Soy | Yes | 6.9 | 9.20% | 2.50% | 26.90% | 7.10% | ● Good source of free amino acids |
| HSP348 | Soy | No | 7 | 9.10% | 1.70% | 18.60% | 7.80% | ● Cost effective nitrogen and carbohydrate source |
| HSP349 | Soy | Yes | 7 | 9.60% | 1.80% | 19.00% | 7.40% | ● Meets papaic digest of soy USP criteria |
| HSP429 | Soy | Yes | 7.1 | 9.80% | 2.70% | 27.00% | 8.80% | ● Supports growth of fastidious bacteria ● Stable in buffered solutions |
| Tatua 5260 | Pea | Yes | 6.4 | 13.60% | 4.40% | 32.30% | 4.80% | ● Good source of free amino acids ● Dairy-free ● Soy-free |
▌产品优势
大拓微生物营养解决方案具有以下优势:
● 大拓用于生产蛋白胨的乳蛋白原料(酪蛋白和乳清蛋白)都是直接来源于新西兰自有农场的奶源,是唯一一家能够全方位供应乳蛋白原料的蛋白胨生产商
● 新西兰来源的乳蛋白原料符合无BSE/TSE要求
● 植物蛋白为非转基因来源
● 大批量生产(高达8MT)降低单位成本
● FSSC 22000-Q 认证确保满足最高水平的质量要求
● 专业的研发团队能够根据不同培养基的需求提供定制化解决方案
● 出厂保质期为60个月
▌大拓蛋白胨的促生长性能




Optocell公司是制药和生物技术市场上游生物工艺监控系统的可靠供应商。凭借对哺乳动物细胞、细菌、酵母和藻类培养的深入了解,Optocell支持在研发、工艺开发和生产阶段对生物工艺进行在线分析。
Optocell is a trusted supplier of monitoring systems for upstream bioprocesses to the Pharma and Biotech market. With the in-depth knowledge of the cultivation of mammalian cells, bacteria, yeast and algae we support the at-line analysis of bioprocesses in the stages of R&D, process development and production.
Optocell的主要产品包括:
BioMajesty
CuBiAn HT270
CuBiAn C125
Reagents
ConSta
LinSta
FocSta
ViaSta
LinSta EASY
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18372041646
传真:15172469628
邮箱:sales@amyjet.com
0.3426